1. Dihydropyrimidinase deficiency: confirmation of the enzyme defect in dihydropyrimidinuria
- Author
-
Peter Vreken, A. H. van Gennip, Jan J. Rotteveel, Jan A.J.M. Bakkeren, A. B. P. Van Kuilenburg, R.A. de Abreu, G.H. van Lenthe, Faculteit der Geneeskunde, and Other departments
- Subjects
medicine.medical_specialty ,Metabolite ,Neurophysiology ,Diseases ,Disturbances of cerebral development in the young child ,Inborn errors of metabolism ,Urine ,Infant, Premature, Diseases ,Gas Chromatography-Mass Spectrometry ,Infant, Newborn, Diseases ,Amidohydrolases ,chemistry.chemical_compound ,Central Nervous System Diseases ,Internal medicine ,Intellectual Disability ,Genetics ,medicine ,Evoked Potentials, Auditory, Brain Stem ,Hemorrhagic Disease of Newborn ,Humans ,Dihydrothymine ,Erfelijke stofwisselingsziekten ,Premature ,Genetics (clinical) ,Chromatography, High Pressure Liquid ,Bronchopulmonary Dysplasia ,Netherlands ,chemistry.chemical_classification ,Asphyxia Neonatorum ,Respiratory Distress Syndrome ,business.industry ,Microcirculation ,Dihydrouracil ,Infant ,Brain ,Uracil ,Newborn ,Thymine ,Enzyme ,Endocrinology ,Pyrimidines ,chemistry ,Liver ,Dihydropyrimidinase ,Cerebrale ontwikkelingsstoornissen bij het jonge kind ,Female ,business - Abstract
Dihydropyrimidinase (DHP, EC 3.5.2.2) is the second enzyme in the degradation pathway of uracil and thymine. It catalyses the degradation of both dihydrouracil and dihydrothymine to N-carbamyl-β-alanine and N-carbamyl-β-aminoisobutyric acid, respectively. So far, four cases of dihydropyrimidinuria (McKusick 222748) have been reported (Duran et al 1991; Henderson et al 1993; Bakkeren et al, personal communication, 1994; Ohba et al 1994). The patients show a variable clinical phenotype comprising seizures or epileptic attacks (3 out of 4 patients) mental retardation (2 patients), growth retardation (1 patient) and dysmorphic features (1 patient). Since these patients excrete large amounts of dihydrouracil and dihydrothymine and moderate amounts of uracil and thymine in their urine, they can easily be detected (Van Gennip et al 1993). On the basis of the characteristic urinary metabolite profile it is assumed that the disease is caused by a deficiency of DHP. The direct measurement of the activity of DHP in patients has been hampered by the fact that the enzyme is almost exclusively expressed in liver tissue. Here, we provide for the first time direct evidence at the enzyme level for a deficient activity of DHP in liver in a patient with dihydropyrimidinuria.
- Published
- 1998
- Full Text
- View/download PDF